▲ Peaking
Business
Merck licenses a KRAS G12D inhibitor for $400M upfront
Merck’s $400 million upfront license for a KRAS G12D inhibitor marks a major bet on next‑generation cancer therapeutics.
Biotech Licensing
3 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Biotech Licensing
This hub groups 3 separate news trends connected to Biotech Licensing, spanning August 24, 2026 through September 28, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 18 article observations and 18 source signals, led by Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
EXCLUSIVE: US weighs allowing most pharma licensing deals with China, sources say
5 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough